New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Argireline

Pancragen vs Argireline

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Skin & Cosmetic
Argireline
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
Half-Life
Short (minutes); sustained gene-regulatory effects
N/A — topical application; effect duration linked to formulation contact time
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
5–10% concentration
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Reduces depth of dynamic expression wrinkles 17–27%
  • Non-invasive topical Botox alternative
  • Smooths forehead, eye area, nasolabial fold lines
  • Widely studied — published clinical efficacy data
  • Synergistic with SNAP-8 for enhanced effect
  • Reduces fine lines around eyes (crow's feet)
  • Improves skin smoothness and texture
  • Well tolerated across all skin types
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Generally very well tolerated
  • At >10%: temporary eyelid/brow ptosis (drooping)
  • Rare: mild redness in sensitive skin
  • No systemic absorption at cosmetic doses
Stacks With